Babu Boga, Vice President of Medicinal Chemistry and Xiang Li, President of the Chemical Division at BioDuro, explore the advantages of a unified FBDD workflow.    The pharmaceutical industry constantly seeks innovative methods to identify novel therapeutic agents. Traditional high-throughput screening (HTS) often faces challenges like high false-positive rates and limited chemical diversity. Fragment-based drug discovery […]

To read this content in full, you need to login.

Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!